SINTX Technologies Reports 82% Revenue Decline in Q2 2025, Plans Strategic Shift to Biomedical Devices

SINTX Technologies, Inc. reported a significant decline in financial performance for the second quarter of 2025, as detailed in its latest 10-Q filing. The company generated total revenue of $151,000 for the three months ended June 30, 2025, a decrease of 82% compared to $859,000 in the same period of 2024. Product revenue fell by 74% to $100,000, while grant and contract revenue dropped 89% to $51,000. For the first half of 2025, total revenue was $520,000, down 66% from $1.5 million in the prior year. The company reported a net loss of $2.3 million for the quarter, slightly higher than the $2.2 million loss in Q2 2024, and a total net loss of $4.6 million for the six-month period, compared to $3.1 million in 2024.

The decline in revenue is attributed to SINTX's strategic shift away from low-margin OEM technical manufacturing contracts, which the company deemed unsustainable for long-term profitability. This transition is part of a broader focus on developing proprietary silicon nitride-based biomedical devices, which are expected to yield higher margins and a stronger competitive position. The company has recently submitted a 510(k) premarket notification to the FDA for its silicon nitride osteotomy wedges, marking its entry into the foot and ankle reconstruction market.

Operationally, SINTX has made significant changes, including the sale of its subsidiary, Technology Assessment and Transfer, Inc. (TA&T), to Tethon Corporation in February 2025. This move is part of the company's strategy to streamline operations and focus on core business areas. Additionally, SINTX has reduced its workforce as part of an effort to improve operational efficiency and reduce costs. As of June 30, 2025, the company reported total assets of $9.2 million, a slight decrease from $9.4 million at the end of 2024, while total liabilities also decreased to $5.2 million from $5.5 million.

Looking ahead, SINTX acknowledges the need for substantial future capital to continue its operations and fund research and development activities. The company is actively seeking additional equity and debt financing, although it cautions that such funding may not be available on favorable terms. The management has expressed uncertainty regarding the company's ability to achieve profitability and positive cash flows from operations in the near future. The ongoing strategic focus on high-growth areas within the healthcare sector aims to position SINTX as a leading provider of innovative medical devices, leveraging its expertise in advanced ceramics and biomaterials.